Modulating function of neural structures near the ear
Stimulation of the facial nerve system (e.g., electrically, electromagnetically, etc.) in ischemic stroke patients will cause dilation of occluded arteries and dilation of surrounding arteries, allowing for blood flow to circumvent the obstruction and reach previously-deprived tissue. The device approaches the facial nerve and its branches in the vicinity of the ear. In use, the device can be inserted into the ear canal and/or placed in proximity to the ear in order to stimulate the facial nerve system non-invasively (e.g., using an electromagnetic field). The device can be used in the emergency treatment of acute stroke or chronically variations for long-term maintenance of blood flow to the brain and stroke prevention. Additional embodiments of the device may be adapted for use on different regions of the body.
Latest Nervive, Inc. Patents:
This application is a continuation-in-part of co-pending U.S. application Ser. No. 13/096,889, filed Apr. 28, 2011, which claims the benefit of U.S. Provisional Application No. 61/397,462, filed on Jun. 14, 2010, entitled “Apparatus and Means of Use for Modulating the Function of Neural Structures within and near to the Middle Ear,” and of U.S. Provisional Application No. 61/330,366, filed on May 2, 2010, entitled “Apparatus and Means of Use for Modulating the Function the Tympanic Plexus, Geniculate Ganglion, Facial Nerve and/or Related Neural Structures of the Middle Ear.” This application also claims the benefit of U.S. Provisional Application No. 61/676,631, filed on Jul. 27, 2012 entitled “Apparatus and means of use for modulating the function of neural structures within and near the middle ear,” U.S. Provisional Application No. 61/624,958, filed on Apr. 16, 2012 entitled “Apparatus and means of use for modulating the function of neural structures within and near the middle ear,” U.S. Provisional Application No. 61/633,371, filed on Feb. 10, 2012 entitled “Apparatus and means of use for modulating the function of neural structures within and near the middle ear,” and U.S. Provisional Application No. 61/630,150, filed on Dec. 6, 2011 entitled “Apparatus and means of use for modulating the function of neural structures within and near the middle.” The entire disclosures of each of the above applications are hereby incorporated by reference herein in their entireties for all purposes.
BACKGROUND OF THE INVENTION1. Field of the invention
The invention relates to apparatuses and methods for treatment of conditions caused directly or indirectly by functions of the vasculature. More specifically, the invention relates to apparatuses and methods for treatment of conditions related to the cranial vasculature, and even more specifically to modulating the function of particular neural structures in the vicinity of the ear for treatment of stroke and other conditions.
2. Description of the Related Art
Stroke is the most common cause of physical disability and the third most common cause of death in the United States. Nearly 900,000 cases of stroke occur each year in the United States, costing $69 billion in healthcare costs. Worldwide, there are nearly 15 million cases of stroke annually; the cost of healthcare services and lost productivity on such a scale is incalculable.
Most cases of stroke are caused by loss of blood flow to the brain because of occlusion of a cerebral artery or carotid artery. Artery occlusion commonly results from (1) a blood clot that is carried by the blood flow into an artery in which it becomes lodged or (2) by formation of a blood clot upon an area of atherosclerotic plaque inside the artery. Loss of blood flow by either mechanism, or by any of several less-common mechanisms, deprives areas of the brain fed by the artery of nutrients and oxygen, leading to cell death and tissue necrosis.
The emergency treatment of stroke is limited. Only one drug, the thrombolytic tissue plasminogen activator (tPA; Alteplase), has been approved for the treatment of acute stroke in the United States. Alteplase acts to dissolve blood clots such as those that occlude cerebral and carotid arteries, causing stroke. As a result, Alteplase can also cause severe intracranial hemorrhage, which is its most serious complication. In order to reduce the chance of intracranial hemorrhage, Alteplase is subject to numerous restrictions that ultimately limit its use to only about 5% of all ischemic stroke patients.
In addition to Alteplase, endovascular techniques employing intra-arterial catheters are used to treat acute stroke. Endovascular techniques, based largely on retrieval of the blood clot from the cerebral or carotid artery or else local administration of thrombolytic drugs directly onto the blood clot, are costly and dangerous, and their use is limited to large hospitals that have highly-trained endovascular physicians on staff. Accordingly, only several thousand stroke patients are treated with endovascular techniques each year in the United States.
A possible treatment of stroke currently under development is electrical stimulation of the sphenopalatine ganglion. This potential treatment involves placement of a metal rod through the roof of the mouth (hard palate) into the vidian canal, which leads to the sphenopalatine ganglion. This device and method has a number of drawbacks. First, placement of the rod requires specialized training and equipment that will restrict its use to the largest and best-equipped hospitals. By inserting the rod through the mouth into the vidian canal, there is a risk of introducing dangerous oral bacteria into the bones of the face. In addition, the blind insertion of the rod into the confines of the vidian canal (which not only leads to the sphenopalatine ganglion but also contains the vidian artery and nerve) risks inducing bleeding or nerve injury. Stroke patients also commonly have difficulty swallowing as part of their neurological injury. Procedures implanting foreign bodies in the mouth, as required by this method, may lead to aspiration in patients who have airways already compromised by the neurological injury from stroke. Finally, this device and method only stimulates the sphenopalatine ganglion and its immediate connections, which in animals has a small effect on blood flow to the brain compared to stimulation of the nerve trunk. Furthermore, this device under development is only applied to one of the two sphenopalatine ganglia, neglecting the potentially additive effect of stimulating both ganglia.
Because of the magnitude of the disease and the limited treatments for it, a significant unmet medical need exists in acute stroke. Thus, there is a need for a solution that solves the problems with current acute stroke treatments noted above, and that: (a) does not require highly-trained endovascular physicians or specialized training for use; (b) does not risk intracranial hemorrhage, aspiration injury, bleeding and nerve injury, or facial bone infection; and (c) is non- or minimally-invasive.
SUMMARY OF THE INVENTIONDisclosed herein is a medical device and method-of-use that solves the above problems and that improves blood flow to the brain by causing dilation of the cerebral and carotid arteries using the body's own regulation of that vascular bed. The invention is an apparatus and method for modulating function of neural structures for treatment of stroke and other conditions. In one embodiment, the apparatus is a stimulator that causes dilation (relaxation) of the cerebral arteries. The cerebral and carotid arteries are innervated by nerves originating in the brainstem (“cranial nerves”), one of which—the facial nerve (also known as the 7th cranial nerve)—acts or else contains or is associated with components that act to regulate those arteries. Stimulation of the facial nerve system in ischemic stroke patients may then cause dilation of the arteries supplying the brain and the head, allowing for blood flow to circumvent an obstruction and reach previously deprived brain tissue. However, stimulation of the facial nerve in hemorrhagic stroke patients may fail to dilate the arteries of the brain and/or head, or else cause constriction of the arteries supplying the brain and/or head, beneficially reducing the likelihood of additional hemorrhage from the site of arterial rupture. The apparatus and method may be used to modify the function of numerous additional neural structures, including the entry region of the facial nerve into the internal auditory canal/internal acoustic meatus, the geniculate ganglion, the tympanic plexus, paratympanic organ(s), the intermediate nerve (of Wrisberg), the pterygopalatine/sphenopalatine nerves and ganglion, the petrosal nerves, the ethmoidal nerves, the palatine nerves, the vidian nerve, the sensory and motor fibers of any of the aforementioned structures, fibers of passage through the aforementioned structures, the communicating branches and connections of the aforementioned structures, and the communicating branches and connections between the aforementioned structures and the ophthalmic, trigeminal, glossopharyngeal, cervical, or vagal nerves.
We have discovered in preclinical/animal studies of subarachnoid hemorrhage and intracerebral hemorrhage that hematomas from these hemorrhages, once stable in size, do not enlarge after stimulation of the facial nerve using stimulation parameters that are otherwise effective at increasing cerebral blood flow in ischemic stroke. In ischemic stroke, we have demonstrated that facial nerve stimulation improves blood flow to the brain and also increases blood flow to the tissues of the head outside of the skull. In contrast, in hemorrhagic stroke, stimulation of the facial nerve does not appear to significantly increase blood flow to the brain, and it dramatically reduces blood flow to the tissues of the head outside of the skull. Thus, most of the embodiments of the device we describe herein are intended to be applied to a stroke patient without knowing if the patient has an ischemic or hemorrhagic stroke.
This property of the facial nerve, i.e., to withhold dilating cranial arteries and increasing cranial blood flow in the condition of hemorrhagic stroke, may reflect sensitivity to blood products, elevated intracranial pressure, or other properties of the hemorrhagic stroke. This property of the facial nerve may in part be mediated by additional neural structures including but not limited to sensory branches of the ophthalmic, trigeminal, glossopharyngeal, cervical, and vagus nerves, or by the circumventricular organs of the brain.
Thus, the invention may have different effects depending on the type of stroke a patient is experiencing. Furthermore, in some methods of use, the invention may serve to diagnose, or support the diagnosis, of stroke subtype (i.e., ischemic stroke versus hemorrhagic stroke) by virtue of the different blood flow responses induced by facial nerve stimulation in the different subtypes of stroke.
In one embodiment, the apparatus approaches the facial nerve and its branches as they pass through and near to the ear in a non-invasive manner. The apparatus can be used in the emergency treatment of acute stroke or can be employed for chronic use in the long-term maintenance of blood flow to the brain, e.g., in people with atherosclerotic disease of the cerebral vasculature in whom blood flow to parts of the brain is chronically compromised, or in patients with certain kinds of dementia. In comparison to the above-described sphenopalatine ganglion stimulator device under development that is inserted into the roof of the mouth, the invention described herein may stimulate the entire facial nerve, which activates the sphenopalatine ganglion as well as several other nerves, nerve branches, and ganglia, and which has a larger and/or more widespread effect on blood flow to the brain.
The apparatus is generally comprised of one or more electrically-conductive elements, such as one or more electrodes or electrically-conductive wires that, when provided electrical current, generates stimulation energy, such as energy in the form of one or more electromagnetic (EM) fields. The stimulation energy might also take the form of heat, ultrasound, radio frequency, microwave, infrared, ultraviolet, and electrical energy. In an embodiment where the stimulation energy takes the electromagnetic (EM) form, the EM field(s) are formed, shaped, distorted, or otherwise generated in a manner to activate the facial nerve system. In some embodiments, the electrically-conductive element is shaped substantially as a coil. In some embodiments, electrically-conductive elements are placed on both sides of the head and/or neck. In some embodiments, the electrically-conductive element is positioned on the head in such a manner as to orient the focus of the EM field or to summate multiple EM fields on a part of the facial nerve. In some embodiments, the orientation of the element is based on one or more anatomical structures of the head or neck. The apparatus can also include an energy regulating housing that can contain or house at least a part of the electrically-conductive element(s). Where there is more than one electrically conductive element, there may be separate housings for each element or a single housing for all elements. The housing electrically insulates the electrically-conductive element and/or dissipates heat in a desirable manner.
The apparatus also comprises a stimulus generator in electrical communication/direct connection with the electrically-conductive element(s) for supplying stimulus energy to the electrically-conductive element(s) for stimulating a neural system, such as one or more components of the facial nerve system in the vicinity of the ear. In some embodiments where the electrically-conductive element takes the form of an array of electrically conductive wires the stimulus generator is attached to these arrays that deliver stimulus energy, whereas in other embodiments the stimulus generator also serves as the arrays of electrically-conductive wire. The apparatus also includes a power source in electrical communication with the stimulus generator for providing power to the stimulus generator to supply the electrical current to the electrically-conductive element (e.g., arrays of electrically-conductive wire). In some embodiments, the stimulus generator is regulated, programmed, or directed by a stimulus controller. In some embodiments, the stimulus controller is guided, directed, programmed, or informed by a variety of sensors. As used herein, the term “stimulator” refers to the overall apparatus and its components.
These and other features, aspects, and advantages of the present invention will become better understood with regard to the following description and accompanying drawings where:
The skilled artisan will understand that the drawings are for illustration purposes only. The drawings are not intended to limit the scope of the present teachings in any way.
DETAILED DESCRIPTION OF THE INVENTIONNeural Structure Modulation Apparatus
The purpose of stimulation of the facial nerve system by some embodiments of the apparatus is to modulate the cranial blood flow. Cranial blood flow generally includes blood flow to the brain and blood flow to other, non-brain tissues of the head and neck. Modulation of blood flow, such as cranial blood flow, includes increasing, decreasing, redistributing, connecting, or disconnecting various subdivisions thereof, or otherwise changing blood flow, such as to the cerebral, carotid, and/or extracerebral arteries, including but not limited to the arteries of the brain, brainstem, meninges, face, scalp, head and neck soft tissues, ears, and eyes of a mammalian subject. As used herein, the term “mammalian subject”, “subject”, or “patient” refers to any mammal, including humans. The term “facial nerve system” as used herein includes, but is not limited to, the facial nerve, the entry region of the facial nerve into the internal auditory canal/internal acoustic meatus, the geniculate ganglion, the tympanic plexus, paratympanic organ(s), the intermediate nerve (of Wrisberg), the pterygopalatine/sphenopalatine nerves and ganglion, the petrosal nerves, the ethmoidal nerves, the palatine nerves, the vidian nerve, the sensory and motor fibers of any of the aforementioned structures, fibers of passage through the aforementioned structures, the communicating branches and connections of the aforementioned structures, and the communicating branches and connections between the aforementioned structures and the ophthalmic, trigeminal, glossopharyngeal, cervical, or vagal nerves. These components of the facial nerve system are in the vicinity of, in proximity to, or are proximate to the ear.
In some embodiments, the apparatus stimulates the facial nerve system in order to increase blood flow to the brain of the subject for treatment of an ischemic stroke, to enhance delivery of a blood-borne pharmacologic agent to treat a condition of the subject, or to dilate arteries for the purpose of allowing passage of an endovascular catheter. In other embodiments, blood flow to the brain or other parts of the head is decreased by stimulation. As used herein, the term “stroke” refers to any type of stroke, and the phrase “stroke caused by atherosclerotic disease” refers specifically to stroke caused by atherosclerotic disease involving the cerebral arteries, which includes about 20% of all stroke. As used herein, the term “condition” refers to any condition for which increase (or reduction in some instances) of blood flow provides treatment or some alleviation of the pathophysiology, signs, or symptoms.
Other disease of abnormal blood flow to the brain may similarly benefit from facial nerve system stimulation. For example, regular facial nerve stimulation may improve blood flow in conditions of dementia or head trauma. As another example, facial nerve stimulation may reduce blood flow in cases of brain tumor, headache, or other hyperemic diseases. Additionally, stimulation of the facial nerve system may offer benefit in disorders of cerebral excitability, such as epilepsy and seizure disorders. Alternatively, stimulation of the facial nerve system may be used to treat disorders of the eye or ear, including those related to blood flow or pressure in those structures. In some embodiments used for these conditions, the orientation of various portions of the apparatus may be adjusted and/or the stimulation parameters may be adjusted to achieve the desired effect or benefit. In some embodiments used for these conditions, the orientation of the apparatus and the stimulation parameters employed are the same as those used for stroke.
As mentioned above, in some cases, stimulation of the facial nerve in hemorrhagic stroke patients may not dilate the arteries of the brain and/or head, but may cause constriction of the arteries supplying the brain and/or head, reducing the likelihood of additional hemorrhage from the site of arterial rupture. Preclinical/animal studies of subarachnoid hemorrhage and intracerebral hemorrhage performed in association with the invention have shown that hematomas from these hemorrhages, once stable in size, do not enlarge after stimulation of the facial nerve using stimulation parameters that are otherwise effective at increasing cerebral blood flow in ischemic stroke.
In ischemic stroke, it has been demonstrated that facial nerve stimulation performed in association with the invention improves blood flow to the brain and also increases blood flow to the tissues of the head outside of the skull. In contrast, in hemorrhagic stroke, stimulation of the facial nerve does not appear to significantly increase blood flow to the brain, and it reduces blood flow to the tissues of the head outside of the skull. Thus, most of the embodiments of the device described herein are intended to be applied to a stroke subject without knowing if the subject has an ischemic or hemorrhagic stroke (‘undifferentiated’ stroke). In this use, the device may provide benefits to the subject, or it may only provide benefit to those subjects with ischemic stroke while doing no harm to those subjects with hemorrhagic stroke.
This property of the facial nerve, i.e., to withhold dilating cranial arteries and increasing cranial blood flow, in the condition of hemorrhagic stroke may reflect sensitivity to blood products, elevated intracranial pressure, or other properties of the hemorrhagic stroke. This property of the facial nerve may in part be mediated by additional neural structures including but not limited to sensory branches of the ophthalmic, trigeminal, glossopharyngeal, cervical, or vagus nerves, or by the circumventricular organs of the brain.
In some embodiments of the apparatus, the energy-regulating housing is composed of two or more materials with different heat conductivities. The energy-regulating housing that touches, faces, or approximates the patient is composed of a material that has a low thermal conductivity whereas all other sides (including the side facing away from the patient) has a high thermal conductivity. The general purpose of this is to direct heat flow from the electrically-conductive elements away from the patient.
Continuing with
In some embodiments, the apparatus is applied to one side of the head, as shown in
As shown in
The stimulus controller 520 can further be used to adjust the stimulus energy for various purposes. For example, the stimulus energy can be adjusted based on one or more physiological or pathophysiological responses of the subject to the stimulus energy (e.g., carotid artery blood flow; cerebral artery blood flow; blood flow to the central nervous system; facial nerve electrical potentials; skin/scalp galvanic responses; skin/scalp blood flow; ear temperature; pupilometry; intraocular pressure; blood flow to the eye; bioelectric potentials; electroencephalogram waveforms; electrophysiological testing of the auditory or vestibular systems; taste sensation; audition; lacrimation; nasal drainage; nasal congestion; salivation; sound sensitivity; face, head, or hand movements or electromyographic potentials; speech production or arrest; sensation of body movement; eye movements; cranial blood flow; direct or indirect activity of a nerve; and severity of neurological dysfunction of the subject). For example, if the subject exhibits certain eye movements, the operator can observe this and respond to this by changing the stimulus energy or certain other parameters associated with the stimulus energy. As another example, the stimulus energy can be adjusted to increase or otherwise control blood flow to the brain of the subject as either the direct treatment of a disease process or else to facilitate the delivery of blood-borne pharmacologic agents as the treatment of a disease process. As another example, the time since the onset of stroke symptoms may inform the stimulus controller 520 to allow the stimulus generator 510 to deliver stimulation energy of certain characteristics or duration. As another example, signal provided to the stimulus controller 520 representing physiological or pathophysiological responses of the subject may direct the stimulus controller 520 to adjust the shape of a positioning component 126. In some embodiments, the operator is replaced by a servocontrol or automatic control mechanism that can detect one or more physiological or pathophysiological responses of the subject to the stimulus energy.
The apparatus of
In some embodiments, the EM coil 100 is between 2 cm and 8 cm in diameter. In some embodiments, the EM coil 100 is a hollow “doughnut” shape. In some embodiments that include repeating loops of wire, the more central loops of wire are progressively raised off the plane of the largest loop so as to form a substantially cone-like shape wherein the apex of the cone is inserted into the ear canal.
In some embodiments, the ear plug 120 is formed from a sound-dampening material. In some embodiments, the ear plug 120 and/or positioning component 126 are formed from heat-adsorbent or heat-resistant materials. In some embodiments, the position of the ear plug 120 and/or positioning component 126 relative to the EM coil 100 offsets the EM coil 100 from a position immediately over the ear canal for the purpose of directing, focusing, or otherwise changing the use of the EM field 101.
Placement of the stimulator against the external ear may be performed, guided, or assisted with various accessory devices such as the positioning component 126 of
Continuing from
In some embodiments, intermittent measurement of blood flow is accomplished by the creation of a uniform magnetic field by an EM coil that is disturbed, disrupted, or otherwise changed by the movement of the blood. In other embodiments, measurement of blood flow may be accomplished by ultrasound, infrared, electrical, optical, microwave, acoustic, mechanical, or other electromagnetic measurements.
Because EM fields can cause heating of metal, or the movement of metal, it may be useful to have a metal detection function as part of the apparatus. In some embodiments (not shown), one or more EM coils used primarily to deliver stimulus energy are employed in a secondary manner to detect metal between the EM coil(s) and the subject, or placed on or implanted in the subject. In these embodiments, one of the EM coils receives and alternating electrical current from the stimulus generator or power source, creating eddy currents in any external metal near the coil. The second EM coil then acts as a magnetometer to detect the eddy current created by the external metal. In some embodiments, the apparatus is equipped with a separate metal detector device.
Multiple EM coils can be assembled into an array for the purpose of combining, shaping, or distorting the EM field in a desirable manner. In some embodiments, the plurality of EM coils is arranged on a single side of the head. In some embodiments, the plurality of EM coils is arranged on both sides of the head in either a symmetric or asymmetric manner. In some embodiments, one or more of the plurality of EM coils is placed in the mouth or under the chin.
In some embodiments, a portion of the facial nerve system such as the geniculate ganglion 302 is centered in the EM field 101. In some embodiments, one or more parts of the facial nerve between the brainstem and the geniculate ganglion (preganglionic facial nerve 341) are centered in the EM field 101. In some embodiments, one or more parts of the facial nerve between the geniculate ganglion and the stylomastoid foramen (postganlionic facial nerve 340) are centered in the EM field 101. In some embodiments, one or more of the plurality of EM coils receive direct electrical current.
As shown in
In some embodiments, the EM field or fields will be generated in a manner that directs action potential conduction in the facial nerve system to progress in a preferred direction, and/or that blocks propagation of the action potential in other directions, by selective direction of electrical current flow 170 through the EM coils. As shown in
Continuing with
In other embodiments, the cap 540 is positioned on a head strap 124 in a manner that orients the generated EM field in a certain direction (not shown). In other embodiments, the cap is associated with positioning components or accessory devices that orient the generated EM field in a certain direction (not shown). In some embodiments, the cap 540 is composed of ferromagnetic material that distorts or modifies an electric or magnetic field in a desirable manner. In some embodiments, the cap 540, EM coils, or housing of the EM coils include one or more fiducial markers that indicate the expected direction or position of the EM field (not shown). In some embodiments, the cap 540 may incorporate aspects of a speculum for visualization of the tympanic membrane/ear drum.
In some embodiments, the coolant cartridge 140 connects to the EM coil in a manner that allows for electrical current to flow through the EM coil. In some embodiments, a connector or other component of the coolant cartridge 140 is irreversibly inactivated or destroyed by connection to the EM coil, thereby preventing reuse of the coolant cartridge 140. In some embodiments, electrical current flow through the EM coil serves to inactivate, destroy, or otherwise render as inoperable the connection between the coolant cartridge 140 and the EM coil.
As shown in
In some embodiments, the stimulus controller 520 is affected, directed, modulated, or instructed by input or information it receives from one or more sensor devices 520. In some embodiments, a sensor device 520 is equipped with one or more sensors that can include physiological sensors 558, temperature sensors 552, blood flow sensors 554, contact sensors 556, and other sensors. In some embodiments, a sensor is directed at or placed on the EM coil 100, cable 530, coolant cartridge 140, or subject 700, or is directed at or placed between a combination of the EM coil 100, cable 530, coolant cartridge 140, and subject 700. Signal or information provided directly or indirectly to the stimulation controller 520 by sensors may, in some embodiments, change or instruct the function of the stimulus generator 510, EM coil 100, or a positioning component (as described for
Additional embodiments of the device may be adapted for use on different regions of the body. For example, an embodiment of the device may be adapted for stimulating the ganglia of the heart, lungs, major blood vessels, gut, or other organs. In such embodiments, the stimulation elements may be arranged as large coils placed on the ventral and/or dorsal aspects of the thorax or abdomen. As another example, an embodiment of the device may be adapted for stimulation of the cranial nerves coursing through the neck. In that embodiment, the stimulation elements may be arranged as a necklace with groupings of elements on one or both sides of the neck surface. In some embodiments, the group of elements focus stimulation energy at a target located deep to the anterior/carotid triangle of the neck. In other embodiments, the group of elements focus stimulation energy at a target located deep to the posterior/occipital triangle of the neck. In some embodiments, the target is the vagus nerve, the accessory nerve, the glossopharyngeal nerve, the hypoglossal nerve, a laryngeal nerve, the ansa cervicalis, a portion of the brachial plexus, or the ganglia of these neural structures. In other embodiments, the target is the carotid bulb or sinus.
Another embodiment of the device may be adapted for stimulation of the neural structures near to, or derived from, the spine. In some embodiments, stimulation elements are arranged as chains longitudinally placed alongside the spine on the posterior surface of the neck or on the back. In some embodiments, the target for stimulation includes the phrenic nerve, the spinal sympathetic chain, an occipital nerve, a portion of the brachial plexus, or the ganglia of these neural structures.
In some embodiments, different regions of the body are stimulated in conjunction with stimulation of the facial nerve.
Neural Structure Modulation Methods
Referring now to
As shown in
With this detection 1004 step achieved, the stimulus controller can be programmed (if necessary) and activated 1014 in embodiments that include such a stimulus controller. In these embodiments, the stimulus controller directs or allows the activation 1018 of the stimulus generator, which then delivers stimulus energy (e.g., electrical current) to the electrically-conductive element (e.g., an EM coil). Thus, stimulation energy can be administered to the subject by the apparatus (e.g., controlled by the operator of the apparatus) for a period of time to generate an electromagnetic field to stimulate the neural system of the subject. In one embodiment, electrical current is delivered 1020 to a first set of EM coils 1020 and delivered 1024 to a second set of EM coils. In some embodiments, the first set of EM coils is composed of EM coils placed on one side of the head and the second set of EM coils is composed of EM coils placed on the other side of the head. In some embodiments, the first set of EM coils are EM coils placed in the ear canal and the second set of EM coils are external EM coils placed on the side of the head. In some embodiments, the delivery 1020 of electrical current to the first set of EM coils is initiated before the delivery 1024 of electrical current to the second set of EM coils. In other embodiments, the delivery 1020 of electrical current to the first set of EM coils is of a different voltage, current, duration, and/or waveform than is the delivery 1024 of electrical current to the second set of EM coils and the electrical current is delivered to the two sets of EM coils simultaneously.
The stimulation energy can be delivered 1024 as electromagnetic pulses. In one example, these pulses are of biphasic shape and of 100-450 microseconds in duration and 0.5-2.0 Tesla field strength at a surface of the apparatus. In another example, the electromagnetic pulses are delivered at 5-20 Hertz frequency in a continuous manner for less than 5 minutes. The stimulation can also be delivered intermittently. In one example, the duration, intensity, frequency, waveform, or other parameter of the administered stimulation energy as a function of blood flow, electroencephalography potentials, intracranial pressure, a duration of the condition of the subject, or other physiological or pathophysiological parameter.
Continuing with
The method also includes providing power via a power source for supplying the stimulus energy to the electrically-conductive elements, such as the EM coils (the power may also be provided automatically, as the device may be constantly connected to or in communication with the power source). The power can be provided via wires connecting the power source to the device. In some methods, supplying stimulus energy to the EM coil or coils modulates blood flow to the brain of the subject or enhances delivery of a blood-borne pharmacologic agent to treat stroke or another condition of the subject. In some methods, supplying stimulus energy to the EM coil or coils modulates electroencephalographic activity (e.g., of the cerebral cortex) to treat or prevent seizures or another condition of neural excitability/inactivity of the subject. The modulation can be performed in the condition or expectation of epilepsy and seizure disorders as either the direct treatment of a disease process or else to prevent onset of the disease process.
If any adjustments are needed or desired regarding the stimulus energy, the method can include adjusting the stimulus energy. For example, the adjustments can be made based on physiological or pathophysiological responses of the subject to the stimulus energy. The method can continue with supplying and adjusting as needed until the method is done. When the method is done (i.e., the treatment is successful and complete), the apparatus can be removed from the subject. If the apparatus has a detachable cap, the method can include detaching the cap and attaching a new cap. If the apparatus has a detachable coolant cartridge, the method can include detaching the coolant cartridge and attaching a new coolant cartridge.
Referring now to
Continuing with
Upon delivery 1120, 1124 of electrical current to the EM coils, the stimulus controller then determines if a minimum stimulation time has not been achieved 1130 for blood flow assessment, and if the minimum stimulation time has not been achieved then the steps described in 1118, 1120, 1124 are repeated. Once the stimulus controller determines that a sufficient duration since the time of activation has been achieved to perform a blood flow measurement, it inactivates the stimulus energy delivery 1132 and activates 1134 the blood flow sensor. The purpose of this step is to determine if the stimulation of the facial nerve system or portion of the facial nerve system has achieved the desired result, namely, to achieve 1140 a threshold for increase of blood flow.
In some embodiments, measurement of blood flow is achieved by use of two or more EM coils, one or more of which serve to magnetize nearby blood while the others serve to detect the release or decay of energy from the magnetized blood once it has moved in a cranial or rostral direction, as described in
The method can also include monitoring one or more physiological or pathophysiological responses of the subject over a period of time. In this method, if it is determined that an adjustment is needed, the method can include adjusting the intensity, frequency, pattern, etc. of the stimulus energy supplied to the EM coils. The adjustment can be made based on the one or more physiological or pathophysiological responses of the subject, the decision of a user, or based on other factors. In some methods, the adjustment can occur automatically without requiring any action by a physician, operator, or other user to make the adjustment. In other methods, the physician, operator, or other user can have access to the monitored responses of the subject, and can control the adjustment based on the monitoring. The method can include continued supplying of stimulus energy to the EM coils with periodic monitoring and adjusting as needed over a period of time to treat the subject, or monitoring can be continuous until a sensor signal is received or a threshold is crossed that causes reactivation of the apparatus leading to the delivery of additional stimulation energy. In this manner, if stimulation is needed or desired of one or more components of the facial nerve system to dilate vessels and treat stroke and/or prevent stroke recurrence, the device can provide such stimulation. This can be done automatically or under the control of a physician, operator, or other user using the device.
In some methods of use, repeating stimulation between intervals of non-stimulation is desirable and expected. In some methods of use, the interval between periods of stimulation is defined by the blood flow response. In other methods of use, the interval between periods of stimulation is predetermined. In some methods of use, the stimulation parameters employed in second and subsequent stimulations is differently set than the initial stimulation parameters. In some embodiments, the stimulation parameters used in the initial or subsequent stimulations are set so as to induce long-term or other types of neural potentiation. In some embodiments, long-term or other types of neural potentiation involve the geniculate ganglion, sphenopalatine ganglion, brainstem, or other neuron groups.
In some methods-of-use, the sensor device detects and/or interprets electroencephalographic potentials, and informs the activity of the stimulus controller based on that information.
In some methods-of-use, the sensor device measures and/or interprets intracranial pressure, and informs the activity of the stimulus controller based on that information.
In some methods-of-use, failure of the apparatus to achieve the desired result will be followed by filling the ear canal with electrically-conductive materials, gels, or solutions, and/or anesthetics and/or pharmacological substances. Once filling of the ear canal is complete, stimulation of the facial nerve system with the apparatus may be attempted again. In some embodiments, the electrically-conductive material, gel, solution, or anesthetics and/or pharmacological substances placed into the ear canal surrounds or otherwise encompasses the EM coils of the apparatus.
In some methods-of-use, failure of the apparatus to achieve the desired result will be followed by advancement of a cannula into the middle ear space. In this situation, a hole is punctured in the ear drum using a sharpened distal end of a cannula. The cannula is equipped so as to allow injection of electrically-conductive materials, gels, solutions, or anesthetics and/or pharmacological substances. Once injection into the middle ear space is complete, stimulation of the facial nerve system with the apparatus may be attempted again. Puncture of the ear drum in order to obtain access to the middle ear space may be facilitated by a stereotaxic device that positions the distal end of the cannula, or by fiber optic visualization. Alternatively, puncture of the ear drum may be accomplished by means of a pressure-sensitive distal end of the cannula or by electrical conductivity changes at the distal end of the cannula.
In some methods-of-use, conduction block of extracranial/distal facial nerve is applied prior to, or during, stimulation of the facial nerve system. In some methods-of-use, the conduction block is accomplished by a local injection of a pharmacological substance into the face or head. In some methods-of-use, the conduction block is accomplished by application of an electrical current across or in the vicinity of the facial nerve trunk external to the middle ear. In some methods-of-use, the conduction block is accomplished by generation of a constant EM field in the vicinity of the facial nerve trunk external to the middle ear.
In some methods-of-use, stimulation of the facial nerve system with EM fields in frequencies of 5-20 Hertz may be optimal for inducing the desired effect. In some methods-of-use, stimulation patterns involving on-off periods may be optimal for inducing the desired effect. In some methods-of-use, stimulation strengths of 0.5-2.0 Tesla (8-32 kT/s at coil surface) may be optimal for inducing the desired effect. In some methods-of-use, stimulation waveform width of 100-450 microseconds may be optimal for inducing the desired effect. In some methods-of-use, stimulation waveform shapes that are substantially bipolar may be optimal for inducing the desired effect. In some methods-of-use, stimulation may be maintained for 0.5 to 5 minutes in duration. In some methods-of-use, the stimulation parameters, direction of electrical current, the orientation of the EM coils, and/or the configuration of the EM coils may be changed depending upon the condition of the patient.
In some methods, use of the apparatus may be appropriate in disorders of cerebrovascular circulation (stroke, chronic cerebrovascular atherosclerosis), head trauma, dementia, headache disorders, or other neurological conditions. In some methods, use of the stimulator may be appropriate prior to procedures that involve the cerebral and carotid arteries, such as endovascular clot retrieval during stroke, endovascular coil and stent placement in aneurysmal subarachnoid hemorrhage, diagnostic angiography, or surgical carotid endarterectomy. In some methods, use of the device may interrupt seizure activity, reduce the likelihood of developing a seizure, or prevent the development of epilepsy. In some methods, use of the apparatus may modulate intracranial pressure. In some embodiments, use of the stimulator may modulate inflammatory and immune reactions within or of the head, neck, and/or elsewhere in the body.
While the present teachings are described in conjunction with various embodiments and methods, it is not intended that the present teachings be limited to such embodiments. On the contrary, the present teachings encompass various alternatives, modifications, and equivalents, as will be appreciated by those of skill in the art. Most of the words used in this specification have the meaning that would be attributed to those words by one skilled in the art. Words specifically defined in the specification have the meaning provided in the context of the present teachings as a whole, and as are typically understood by those skilled in the art. In the event that a conflict arises between an art-understood definition of a word or phrase and a definition of the word or phrase as specifically taught in this specification, the specification shall control. It must be noted that, as used in the specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise.
Claims
1. An apparatus, comprising:
- one or more electrically-conductive elements;
- a positioning ear piece insertable into an ear canal of a subject;
- an energy-regulating housing adapted to contain the one or more electrically-conductive elements, the energy regulating housing adapted to electrically insulate the one or more electrically-conductive elements and dissipate heat, the energy-regulating housing comprising: a first surface configured to face a subject and rest against an external ear of the subject and comprise materials having lower thermal conductivity than other surfaces of the housing, a second surface configured to enclose the positioning ear piece and comprising heat resistant materials, and a third surface configured to face away from the subject and comprising materials having a higher thermal conductivity than the first surface, wherein the first, second, and third surfaces are electrically insulating;
- a stimulus generator in electrical communication with the one or more electrically-conductive elements and configured to deliver stimulus energy to the one or more electrically-conductive elements in a manner that allows the one or more electrically-conductive elements to generate an electromagnetic field to stimulate a portion of a neural system of the subject; and
- a power source in communication with the stimulus generator for providing stimulus energy to the stimulus generator.
2. The apparatus of claim 1, wherein the delivered stimulus energy is electrical energy.
3. The apparatus of claim 1, wherein the one or more electrically-conductive elements are shaped substantially as a coil, and wherein the energy-regulating housing is configured to be in substantial contact with a lateral surface of a head of the subject.
4. The apparatus of claim 1, wherein the energy-regulating housing is configured to be in substantial contact with a pinna of an ear of the subject.
5. The apparatus of claim 2, wherein the one or more electrically-conductive elements are adapted to focus the generated electromagnetic field upon a single target that is a particular distance from a contact surface of the one or more electrically-conductive elements.
6. The apparatus of claim 5, wherein the particular distance is 2-4 cm from the contact surface of the one or more electrically-conductive elements.
7. The apparatus of claim 1, wherein the apparatus further comprises a case associated with the energy-regulating housing, the case comprising a component that absorbs or dissipates heat.
8. The apparatus of claim 7, wherein the component of the case comprises a phase-change material.
9. The apparatus of claim 7, wherein the component of the case comprises a heat sink.
10. The apparatus of claim 7, wherein the component of the case comprises a radiator.
11. The apparatus of claim 1, wherein the positioning ear piece is configured to create an angle between a surface of the energy-regulating housing and a surface of the subject.
12. The apparatus of claim 1, wherein the energy-regulating housing comprises a cone of ferromagnetic material.
13. The apparatus of claim 2, further comprising an automated or programmable stimulus controller configured to control the stimulus generator.
14. The apparatus of claim 2, further comprising one or more sensors or sensor functions configured to be applied to the subject or the apparatus and configured to provide input for regulating the delivery of stimulus energy to the one or more electrically-conductive elements by the stimulus generator.
15. The apparatus of claim 14, wherein the one or more sensors are configured to measure blood flow.
16. The apparatus of claim 14, wherein the one or more sensors are configured to detect metal in a vicinity of the energy-regulating housing, within a vicinity of an area of application to the subject, or implanted within the subject in a vicinity of an ear of the subject.
17. The apparatus of claim 14, wherein the one or more electrically-conductive elements comprise the one or more sensors.
18. The apparatus of claim 1, wherein the one or more electrically-conductive elements comprises sensor configured to magnetize blood components or detect signals emitted by magnetized blood components.
19. The apparatus of claim 18, wherein the one or more electrically-conductive elements comprising the sensor is configured to create a magnetic flux or measure magnetic disturbance created by blood flow.
20. The apparatus of claim 1, wherein the one or more electrically-conductive elements are configured to reside on opposing sides of the head of the subject such that the energy-regulating housing of the one or more electrically-conductive elements is in substantial contact with the pinnae of the ears.
21. The apparatus of claim 2, wherein the one or more electrically conductive elements are configured to be positioned on opposing sides of a head of the subject and are configured to provide stimulus energy from the stimulus generator to create a single electromagnetic field across the diameter of the head of the subject.
22. The apparatus of claim 21, wherein a portion of the one or more electrically-conductive elements is configured to reside within a mouth or an ear canal of the subject or underneath a chin of the subject to create, in conjunction with the one or more electrically conductive elements that are configured to be positioned on opposing sides of the head of the subject, the single electromagnetic field that crosses the diameter of the head of the subject.
23. The apparatus of claim 1, wherein the neural system is a facial nerve system.
24. The apparatus of claim 1, wherein the one or more electrically-conductive elements are configured for stimulation of a facial nerve system of the subject having a hemorrhagic stroke, the stimulation to constrict arteries supplying blood flow to a brain or a head of the subject, thereby reducing a likelihood of additional hemorrhage from a site of arterial rupture.
25. An apparatus, comprising:
- one or more coiled electrically-conductive elements;
- an energy-regulating housing adapted to contain the one or more coiled electrically-conductive elements, the energy regulating housing adapted to electrically insulate the one or more coiled electrically-conductive elements and dissipate heat;
- an ear plug projecting from the energy regulating housing and configured to enter an ear canal of a mammalian subject to position the energy-regulating housing containing the one or more coiled electrically-conductive elements such that a plane of the one or more coiled elements is orthogonal to an axis of the ear canal, the one or more coiled elements configured to be oriented toward the ear canal to provide a stimulating electromagnetic field to the ear canal, wherein: the ear plug encloses a ferromagnetic material configured to shape, amplify, or focus, within the ear canal, the stimulating electromagnetic field generated by the one or more coiled elements, a length of the ferromagnetic material is configured to be axially aligned with the axis of the ear canal, the length of the ferromagnetic material depending inversely on a radius of the one or more coiled elements and the length of the ferromagnetic material being substantially perpendicular to a plane of the one or more coiled elements,
- a stimulus generator in electrical communication with the one or more electrically-conductive elements and configured to deliver stimulus energy to the one or more electrically-conductive elements in a manner that allows the one or more coiled electrically-conductive elements to generate the stimulating electromagnetic field to stimulate a portion of a neural system of a subject; and
- a power source in communication with the stimulus generator for providing stimulus energy to the stimulus generator.
26. The apparatus of claim 25, wherein the energy-regulating housing is configured to be in substantial contact with a lateral surface of a head of the subject.
27. The apparatus of claim 25, wherein the one or more coiled electrically-conductive elements are adapted to focus the generated electromagnetic field upon a single target that is a particular distance from a contact surface of the one or more coiled electrically-conductive elements.
28. The apparatus of claim 25, wherein the ear plug comprises an electrically-conductive element.
29. The apparatus of claim 25, wherein the ferromagnetic material is configured to project from a surface of the energy-regulating housing.
30. The apparatus of claim 25, wherein the ferromagnetic material and a perimeter of the one or more coiled electrically-conductive elements form an angle which measures in between 20 to 90 degrees.
31. The apparatus of claim 25, further comprising one or more sensors or sensor functions configured to be applied to the subject or the apparatus and configured to provide input for regulating the delivery of stimulus energy to the one or more coiled electrically-conductive elements by the stimulus generator.
32. The apparatus of claim 31, wherein the one or more sensors are configured to measure blood flow.
33. The apparatus of claim 25, wherein the one or more coiled electrically conductive elements are configured to be positioned on opposing sides of a head of the subject and are configured to provide stimulus energy from the stimulus generator to create a single electromagnetic field across the diameter of the head of the subject.
34. The apparatus of claim 25, wherein the ferromagnetic material is shaped along the length as a horseshoe with a substantially 180 degree bend on a side proximal to the one or more coiled elements to focus the electromagnetic field toward an end of the ferromagnetic material distal to the one or more coiled elements and into the ear canal, and wherein the one or more coiled elements, the energy-regulating housing, the ear plug, and the ferromagnetic material have axially aligned central openings.
2876767 | March 1959 | Wasserman |
3629521 | December 1971 | Puharich et al. |
4044774 | August 30, 1977 | Corbin et al. |
4696287 | September 29, 1987 | Hortmann et al. |
5116304 | May 26, 1992 | Cadwell |
5441495 | August 15, 1995 | Liboff et al. |
5461215 | October 24, 1995 | Haldeman |
5607461 | March 4, 1997 | Lathrop |
5922016 | July 13, 1999 | Wagner |
5991664 | November 23, 1999 | Seligman |
6078838 | June 20, 2000 | Rubinstein |
6093417 | July 25, 2000 | Petrus |
6179770 | January 30, 2001 | Mould |
6179771 | January 30, 2001 | Mueller |
6179772 | January 30, 2001 | Blackwell |
6213933 | April 10, 2001 | Lin |
6310961 | October 30, 2001 | Oliveira et al. |
6408855 | June 25, 2002 | Berrang et al. |
6425852 | July 30, 2002 | Epstein et al. |
6468199 | October 22, 2002 | Satou et al. |
6488617 | December 3, 2002 | Katz |
6526318 | February 25, 2003 | Ansarinia |
6551233 | April 22, 2003 | Perreault et al. |
6629399 | October 7, 2003 | Sarles et al. |
6663556 | December 16, 2003 | Barker |
6849040 | February 1, 2005 | Ruohonen et al. |
6853858 | February 8, 2005 | Shalev |
6900420 | May 31, 2005 | Markegård et al. |
6926660 | August 9, 2005 | Miller |
7103417 | September 5, 2006 | Segel et al. |
7117033 | October 3, 2006 | Shalev et al. |
7120489 | October 10, 2006 | Shalev et al. |
7146209 | December 5, 2006 | Gross et al. |
7146227 | December 5, 2006 | Dadd et al. |
7149574 | December 12, 2006 | Yun et al. |
7340298 | March 4, 2008 | Barbut |
7363076 | April 22, 2008 | Yun et al. |
7367936 | May 6, 2008 | Myers et al. |
7396326 | July 8, 2008 | Riehl et al. |
7407478 | August 5, 2008 | Zangen et al. |
7519435 | April 14, 2009 | Parker et al. |
7561919 | July 14, 2009 | Shalev et al. |
7580754 | August 25, 2009 | Zhang et al. |
7591776 | September 22, 2009 | Phillips et al. |
7591779 | September 22, 2009 | Kalinowski et al. |
7636597 | December 22, 2009 | Gross et al. |
7640062 | December 29, 2009 | Shalev |
7658704 | February 9, 2010 | Fox et al. |
7684858 | March 23, 2010 | He et al. |
7684859 | March 23, 2010 | Shalev et al. |
7711432 | May 4, 2010 | Thimineur et al. |
7771341 | August 10, 2010 | Rogers |
7854232 | December 21, 2010 | Aho et al. |
7946973 | May 24, 2011 | Peterchev |
7973635 | July 5, 2011 | Baarman et al. |
8052591 | November 8, 2011 | Mishelevich et al. |
8267850 | September 18, 2012 | Schneider et al. |
8277371 | October 2, 2012 | Zangen et al. |
8388510 | March 5, 2013 | Zangen et al. |
8396566 | March 12, 2013 | Kassab et al. |
8412342 | April 2, 2013 | Zhang et al. |
8460167 | June 11, 2013 | Chornenky et al. |
8523753 | September 3, 2013 | Schneider et al. |
8545378 | October 1, 2013 | Peterchev |
8591392 | November 26, 2013 | Bentwich et al. |
8723628 | May 13, 2014 | Mishelevich et al. |
8771163 | July 8, 2014 | Zangen et al. |
8795148 | August 5, 2014 | Schneider et al. |
20010031906 | October 18, 2001 | Ishikawa et al. |
20020026125 | February 28, 2002 | Leysieffer |
20020151886 | October 17, 2002 | Wood |
20030004393 | January 2, 2003 | Ewing et al. |
20030195588 | October 16, 2003 | Fischell et al. |
20050027251 | February 3, 2005 | Masters |
20050222486 | October 6, 2005 | Shin et al. |
20050288664 | December 29, 2005 | Ford et al. |
20060162952 | July 27, 2006 | Olbrich et al. |
20060187607 | August 24, 2006 | Mo |
20060287566 | December 21, 2006 | Zangen et al. |
20060287689 | December 21, 2006 | Debruyne et al. |
20070118197 | May 24, 2007 | Loeb |
20080027513 | January 31, 2008 | Carbunaru |
20080058581 | March 6, 2008 | Aho |
20080082141 | April 3, 2008 | Risi |
20080097549 | April 24, 2008 | Colbaugh et al. |
20080154343 | June 26, 2008 | Li et al. |
20080224808 | September 18, 2008 | Ghiron et al. |
20080262287 | October 23, 2008 | Dussau |
20080262468 | October 23, 2008 | Clifford et al. |
20090018384 | January 15, 2009 | Boyden et al. |
20090099405 | April 16, 2009 | Schneider et al. |
20090108969 | April 30, 2009 | Sims et al. |
20090131739 | May 21, 2009 | Shalev |
20090174407 | July 9, 2009 | Han et al. |
20090187098 | July 23, 2009 | Makower et al. |
20100016650 | January 21, 2010 | Phillips et al. |
20100094076 | April 15, 2010 | Phillips |
20100113959 | May 6, 2010 | Pascual-Leone et al. |
20100114184 | May 6, 2010 | Degtyar et al. |
20100193506 | August 5, 2010 | Nagai et al. |
20100286470 | November 11, 2010 | Schneider et al. |
20100331602 | December 30, 2010 | Mishelevich et al. |
20110082326 | April 7, 2011 | Mishelevich et al. |
20110125203 | May 26, 2011 | Simon et al. |
20110218381 | September 8, 2011 | Ruohonen |
20110263925 | October 27, 2011 | Bratton |
20120101366 | April 26, 2012 | Ruohonen et al. |
20120149969 | June 14, 2012 | Farone |
20130096363 | April 18, 2013 | Schneider et al. |
20130267763 | October 10, 2013 | Schneider et al. |
20130278369 | October 24, 2013 | Shepard et al. |
20130304159 | November 14, 2013 | Simon et al. |
20130317281 | November 28, 2013 | Schneider et al. |
20140081072 | March 20, 2014 | Huang et al. |
20140085031 | March 27, 2014 | Nomura et al. |
20140163305 | June 12, 2014 | Watterson |
1 135 348 | November 1982 | CA |
2 021 506 | July 1990 | CA |
2 608 084 | November 2006 | CA |
2 610 991 | December 2006 | CA |
86105171 | March 1987 | CN |
101366666 | February 2009 | CN |
101985058 | March 2011 | CN |
102013579 | April 2011 | CN |
202605538 | December 2012 | CN |
202637725 | January 2013 | CN |
202961526 | June 2013 | CN |
10046275 | March 2002 | DE |
0 214 527 | March 1987 | EP |
0 408 230 | January 1991 | EP |
1 671 672 | June 2006 | EP |
1 890 762 | February 2008 | EP |
1 145 738 | November 2008 | EP |
1 890 615 | September 2009 | EP |
2 384 223 | November 2011 | EP |
2 520 334 | November 2012 | EP |
2 666 515 | November 2013 | EP |
S62-44250 | February 1987 | JP |
2003-503119 | January 2003 | JP |
2003-180847 | July 2003 | JP |
2006-515999 | June 2006 | JP |
2008-522725 | July 2008 | JP |
2008-528145 | July 2008 | JP |
2010-213979 | September 2010 | JP |
2012 115 948 | October 2013 | RU |
WO 95/25417 | September 1995 | WO |
WO 97/00639 | January 1997 | WO |
WO 01/00273 | January 2001 | WO |
WO 01/97095 | December 2001 | WO |
WO 01/97905 | December 2001 | WO |
WO 02/32504 | April 2002 | WO |
WO 02/089902 | November 2002 | WO |
WO 03/026478 | April 2003 | WO |
WO 03/090863 | November 2003 | WO |
WO 2004/036603 | April 2004 | WO |
WO 2004/043217 | May 2004 | WO |
WO 2004/043218 | May 2004 | WO |
WO 2004/043334 | May 2004 | WO |
WO 2004/045242 | May 2004 | WO |
WO 2004/087255 | October 2004 | WO |
WO 2005/002346 | January 2005 | WO |
WO 2005/030025 | April 2005 | WO |
WO 2006/014896 | February 2006 | WO |
WO 2006/021957 | March 2006 | WO |
WO 2006/040690 | April 2006 | WO |
WO 2006/057734 | June 2006 | WO |
WO 2006/076708 | July 2006 | WO |
WO 2006/078924 | July 2006 | WO |
WO 2006/083675 | August 2006 | WO |
WO 2006/119512 | November 2006 | WO |
WO 2006/134598 | December 2006 | WO |
WO 2006/135853 | December 2006 | WO |
WO 2007/137335 | December 2007 | WO |
WO 2008/030485 | March 2008 | WO |
WO 2008/048471 | April 2008 | WO |
WO 2008/052166 | May 2008 | WO |
WO 2008/112915 | September 2008 | WO |
WO 2008/130533 | October 2008 | WO |
WO 2008/150963 | December 2008 | WO |
WO 2009/011939 | January 2009 | WO |
WO 2009/013881 | January 2009 | WO |
WO 2009/033144 | March 2009 | WO |
WO 2009/033150 | March 2009 | WO |
WO 2009/033192 | March 2009 | WO |
WO 2009/037689 | March 2009 | WO |
WO 2009/042863 | April 2009 | WO |
WO 2009/047370 | April 2009 | WO |
WO 2009/100633 | August 2009 | WO |
WO 2009/138428 | November 2009 | WO |
WO 2009/143171 | November 2009 | WO |
WO 2010/014894 | February 2010 | WO |
WO 2010/033909 | March 2010 | WO |
WO 2010/049576 | May 2010 | WO |
WO 2010/062622 | June 2010 | WO |
WO 2010/080879 | July 2010 | WO |
WO 2011/060699 | May 2011 | WO |
WO 2012/048319 | October 2011 | WO |
WO 2012/045079 | April 2012 | WO |
WO 2012/090068 | July 2012 | WO |
WO 2012/117166 | September 2012 | WO |
WO 2013/006670 | January 2013 | WO |
WO 2013/116235 | August 2013 | WO |
WO 2013/126176 | August 2013 | WO |
WO 2014/022236 | February 2014 | WO |
WO 2014/097571 | June 2014 | WO |
- PCT International Search Report and Written Opinion, PCT Application No. PCT/US2012/067801, Apr. 19, 2013, twelve pages.
- Bar-Shir, A. et al., “Late Stimulation of the Sphenopalatine-Ganglion in Ischemic Rats: Improvement in N-Acetyl-Aspartate Levels and Diffusion Weighted Imaging Characteristcs as Seen by MR,” Journal of Magnetic Resonance Imaging, 2010, pp. 1355-1363, vol. 31.
- Brainsgate, “Ischemic Stroke System,” 2005, two pages. [Online] [Retrieved Oct. 19, 2011] Retrieved from the Internet <URL:http://www.brainsgate.com/eng/page.php?id=11&instance—id=8>.
- Khurana, D. et al., “Implant for Augmentation of Cerebral Blood Flow Trial 1: A pilot Study Evaluating the Safety and Effectiveness of the Ischaemic Stroke System for Treatment of Acute Ischaemic Stroke,” International Journal of Stroke, Dec. 2009, pp. 480-485, vol. 4.
- PCT International Search Report and Written Opinion, PCT Application No. PCT/US2011/034378, Aug. 8, 2011, seven pages.
- Yarnitsky, D. et al., “Blood-brain Barrier Opened by Stimulation of the Parasympathetic Sphenopalatine Ganglion: A New Method for Macromolecule Deliver to the Brain,” Journal of Neurosurgery, 2004, pp. 303-309, vol. 101.
- Yarnitsky, D. et al., “Increased BBB Permeability by Parasympathetic Sphenopalatine Ganglion Stimulation in Dogs,” Brain Research, 2004, five pages.
- Yarnitsky, D. et al., “Reversal of Cerebral Vasospasm by Sphenopalatine Ganglion Stimulation in a Dog Model of Subarachnoid Hemorrahage,” Surgical Neurology, 2005, pp. 5-11, vol. 64.
- Australian Government, IP Australia, Patent Examination Report No. 1, Australian Patent Application No. 2011248487, Feb. 17, 2015, three pages.
- European Patent Office, Search Report and Opinion, European Patent Application No. 11778023.9, Jul. 31, 2014, eight pages.
- Goadsby, P.J., “Characteristics of facial nerve-elicited cerebral vasodilatation determined using laser Doppler flowmetry,” Database Accession No. NLM1992824, Jan. 1991, XP002711162, Database Medline, U.S. National Library of Medicine (NLM), Bethesda, Maryland, U.S.
- Japanese Patent Office, Office Action, Japanese Patent Application No. 2013-509125, Oct. 1, 2014, eight pages.
- State Intellectual Property Office of the People's Republic of China, First Office Action, Chinese Patent Application No. 201180022239.3, Apr. 4, 2014, fifteen pages.
- Stjernschantz, J. et al., “Vasomotor effects of facial nerve stimulation: noncholinergic vasodilation in the eye,” Acta Physiologica Scandinavica, May 1, 1980, pp. 45-50, vol. 109, No. 1, Scandinavian Physiological Society.
- United States Office Action, U.S. Appl. No. 13/096,889, Jun. 18, 2014, twenty-five pages.
- United States Office Action, U.S. Appl. No. 13/096,889, Nov. 6, 2014, twenty-seven pages.
- State Intellectual Property Office of the People's Republic of China, First Office Action, Chinese Patent Application No. 2012800598917, Mar. 19, 2015, sixteen pages.
- United States Office Action, U.S. Appl. No. 13/096,889, Jun. 26, 2015, thirteen pages.
- European Patent Office, Search Report and Opinion, European Patent Application No. 12856454.9, Oct. 19, 2015, six pages.
Type: Grant
Filed: Dec 3, 2012
Date of Patent: Mar 1, 2016
Patent Publication Number: 20130150653
Assignee: Nervive, Inc. (Orinda, CA)
Inventor: Mark Klingler Borsody (Orinda, CA)
Primary Examiner: Christine H Matthews
Assistant Examiner: Joshua D Lannu
Application Number: 13/692,226
International Classification: A61N 2/00 (20060101); A61N 2/02 (20060101); A61N 5/06 (20060101); A61N 7/00 (20060101); A61N 1/40 (20060101);